Flumethasone Pivalate

Summary

Flumethasone Pivalate (CHEMBL1200877) is an approved small-molecule anti-inflammatory drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 494.6 Da · C27H36F2O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200877
Name	Flumethasone Pivalate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	443980
ChEBI	CHEBI:31620
Molecular formula	C27H36F2O6
Molecular weight	494.6
InChIKey	JWRMHDSINXPDHB-OJAGFMMFSA-N

SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F

IUPAC name: [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate

Pharmacological roles (ChEBI): anti-inflammatory drug, antipruritic drug.

Also known as: Flumetasone pivalate, Flumethasone pivalate, Locorten, Locorten-vioform, NSC-107680, SID855730, FLUMETHASONE PIVALATE, SID56423133, FLUMETHAZONE PIVALATE, flumetasone pivalate

Patent coverage: 1,578 distinct patent families (6,132 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Nuclear receptor ROR-gamma, Androgen receptor, Progesterone receptor.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
AR	5.86	AC50	1396	nM	CHEMBL_ACT_25203868
PGR	5.23	AC50	5845	nM	CHEMBL_ACT_25204801

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).